Morgan Stanley lowered the firm’s price target on Adagene to $4.60 from $5 and keeps an Overweight rating on the shares. The firm lowered its price target based on updated Yervoy U.S. sales projections and PD-1 sales in China while also moving forward its net cash and shares outstanding projections to 2024 from 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADAG: